Evaluation of 18F-fluciclovine (FACBC) PET/MR Uptake in Participants With Glioma

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

October 22, 2019

Primary Completion Date

May 18, 2021

Study Completion Date

September 30, 2021

Conditions
Glioma
Interventions
DRUG

18F-fluciclovine

Prior to beginning PET imaging, 18F-fluciclovine will be administered as an intravenous bolus injection followed by a 10mL saline flush. 18F-fluciclovine will be injected through a cannula (or indwelling catheter) in an antecubital vein or another vein that will provide access. The administration site will be evaluated pre- and post-administration for any reaction. Documentation of administration to a participant will be recorded or as part of the scan upload, including date, prescription number, dose activity (as measured at time of administration), total volume, and start/stop time of administration.

Trial Locations (1)

15213

UPMC Hospitals, Pittsburgh

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Blue Earth Diagnostics

INDUSTRY

lead

James Mountz

OTHER

NCT04114370 - Evaluation of 18F-fluciclovine (FACBC) PET/MR Uptake in Participants With Glioma | Biotech Hunter | Biotech Hunter